Target Name: RASSF7
NCBI ID: G8045
Other Name(s): RASSF7 variant 1 | MGC126069 | RASF7_HUMAN | C11orf13 | HRC1 | OTTHUMP00000162847 | Ras association (RalGDS/AF-6) domain family (N-terminal) member 7 | HRAS1 | HRAS1-related cluster-1 | FAP88 | MGC126070 | CFAP88 | Ras association domain family member 7 | Ras association domain family protein 7 (RASSF7) | Ras association (RalGDS/AF-6) domain family 7 | OTTHUMP00000162848 | Ras association domain-containing protein 7 (isoform 1) | Ras association domain-containing protein 7 | HRAS1-related cluster protein 1 | Ras association domain family member 7, transcript variant 1

Targeting RASSF7 for Therapeutic Solutions

The rapid progress of the scientific understanding of the human genome has led to the identification of numerous potential drug targets and biomarkers. One of these targets is RASSF7 (RASSF7 variant 1), a gene that has been identified in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will explore the research on RASSF7 and its potential as a drug target.

Current Treatment Overview

RASSF7 is a gene that has been associated with the development and progression of various diseases. Its role in cancer progression is well established, with studies indicating that RASSF7 is involved in the regulation of cell cycle progression and the development of cancer. RASSF7 has also been linked to the development of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its association with disease, RASSF7 has also been identified as a potential drug target. The use of RNA interference (RNAi) technology has allowed researchers to reduce the amount of RASSF7mRNA in cancer cells, leading to a decrease in cell proliferation. This suggests that targeting RASSF7 may be an effective way to treat cancer.

Drugs That Target RASSF7

Currently, there are several drugs that are being developed or have been approved for the treatment of diseases associated with RASSF7. One of the most well-known drugs is ALZ-8016, a drug that is being developed by Roche for the treatment of Alzheimer's disease. ALZ-8016 uses RNAi technology to reduce the amount of RASSF7mRNA in the brains of individuals with Alzheimer's disease, leading to a decrease in the number of new neurons that are formed.

Another drug that targets RASSF7 is TST-1028, a drug that is being developed by Targeting Interactions for Therapeutic Solutions (TITS). TST-1028 is a small molecule that is designed to inhibit the activity of RASSF7, leading to a decrease in the amount of RASSF7mRNA that is produced in cancer cells.

Targeting RASSF7 Using RNA Interference

RNA interference (RNAi) is a technology that has been used to reduce the amount of RASSF7mRNA in cancer cells. RNAi works by using small interfering RNA (siRNA) molecules to target the specific mRNAs that are being produced by a gene. In cancer cells, RASSF7mRNA is produced at high levels, and RNAi can be used to reduce the amount of this mRNA.

RNAi can be used to treat a variety of diseases associated with RASSF7, including cancer, neurodegenerative disorders, and autoimmune diseases. In the case of cancer, RNAi has been used to treat a variety of diseases, including breast cancer, ovarian cancer, and prostate cancer.

RNAi-based Therapies for RASSF7- associated Diseases

RNAi-based therapies have been approved for the treatment of a variety of diseases associated with RASSF7. One of the most well-known drugs is ALZ-8016, a drug that is being developed by Roche for the treatment of Alzheimer's disease. ALZ-8016 uses RNAi technology to reduce the amount of RASSF7mRNA in the brains of individuals with Alzheimer's disease, leading to a decrease in the number of new neurons that are formed.

Another drug that targets RASSF7 is TST-1028, a drug that is being developed by Targeting Interactions for Therapeutic Solutions (TITS). TST-1028 is a small molecule that is designed to inhibit the activity of RASSF7, leading to a decrease in the amount of RASSF7mRNA that is produced in cancer cells.

Conclusion

RASSF7 is a gene that has been associated with the development and progression of various diseases. Its role in cancer progression is well established, and RNAi technology has been used to reduce the amount of RASSF7mRNA in cancer cells. Currently, several drugs are being developed or have been approved for the treatment of diseases associated with RASSF7, including ALZ-8016 and TST-1028. These drugs use RNAi technology to reduce the amount of RASSF7mRNA, leading to a decrease in the number of new neurons or cells that are formed in the affected tissue. Further research is needed to

Protein Name: Ras Association Domain Family Member 7

Functions: Negatively regulates stress-induced JNK activation and apoptosis by promoting MAP2K7 phosphorylation and inhibiting its ability to activate JNK. Following prolonged stress, anti-apoptotic effect stops because of degradation of RASSF7 protein via the ubiquitin-proteasome pathway. Required for the activation of AURKB and chromosomal congression during mitosis where it stimulates microtubule polymerization

More Common Targets

RASSF8 | RASSF8-AS1 | RASSF9 | RAVER1 | RAVER2 | RAX | RAX2 | RB1 | RB1-DT | RB1CC1 | RBAK | RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5